Haisco Pharmaceutical Group Co., Ltd. announced that it will receive CNY 358,000,000 in a round of funding on May 9, 2022. The transaction will include participation from Haisco Holdings Pte. Ltd. for CNY 286,400,000 to retain 80% stake in the company and Haisight Holdings PTE.LTD. for CNY 71,600,000 to retain 20% stake in the company.

The capital increase will be fully included in the capital reserve, and the shareholding ratio held by the company. The transaction has been approved at the 36th meeting of the 4th board of directors of the company and still needs to be approved by the general meeting of shareholders.